Showing results (181-190 of 501) with videos related to
Sort By:
Pageof 51
Nature Communications|July 17, 2019
Association of imputed prostate cancer transcriptome with disease risk reveals novel mechanismsNima C Emami, Linda Kachuri, Travis J Meyers, et al.European Urology Oncology|July 9, 2023
The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing LiteratureAkshay Sood, Amar U Kishan, Christopher P Evans, et al.Cancer|December 4, 2019
Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012Santino S Butler, Vinayak Muralidhar, Shuang G Zhao, et al.Nature Communications|August 30, 2019
Author Correction: Association of imputed prostate cancer transcriptome with disease risk reveals novel mechanismsNima C Emami, Linda Kachuri, Travis J Meyers, et al.Molecular Cancer Therapeutics|August 24, 2022
PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM-Deficient Tumors and Potent Synergy With PARP InhibitorsAnish Thomas, Shaun D Fontaine, Morgan E Diolaiti, et al.Oncotarget|April 15, 2014
The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancerJohn R Prensner, Anirban Sahu, Matthew K Iyer, et al.Radiation Oncology (London, England)|July 10, 2013
A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomyWilliam C Jackson, Skyler B Johnson, Darren Li, et al.Science Signaling|May 30, 2019
KRAS<sup>G12C</sup> inhibition produces a driver-limited state revealing collateral dependenciesKevin Lou, Veronica Steri, Alex Y Ge, et al.Nature Methods|July 16, 2024
A systematic search for RNA structural switches across the human transcriptomeMatvei Khoroshkin, Daniel Asarnow, Shaopu Zhou, et al.Urologic Oncology|May 8, 2019
The current state of randomized clinical trial evidence for prostate brachytherapyRobert T Dess, Payal D Soni, William C Jackson, et al.Pageof 51